DK1719774T3 - Terapeutisk middel mod diabetisk makulaødem - Google Patents

Terapeutisk middel mod diabetisk makulaødem

Info

Publication number
DK1719774T3
DK1719774T3 DK05704239.2T DK05704239T DK1719774T3 DK 1719774 T3 DK1719774 T3 DK 1719774T3 DK 05704239 T DK05704239 T DK 05704239T DK 1719774 T3 DK1719774 T3 DK 1719774T3
Authority
DK
Denmark
Prior art keywords
diabetic
prophylactic
diabetic maculopathy
therapeutic agent
hydrogen atom
Prior art date
Application number
DK05704239.2T
Other languages
English (en)
Inventor
Noriaki Kato
Hiroshi Nagano
Kaori Taniko
Takahito Jomori
Original Assignee
Sanwa Kagaku Kenkyusho Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanwa Kagaku Kenkyusho Co filed Critical Sanwa Kagaku Kenkyusho Co
Priority claimed from PCT/JP2005/001187 external-priority patent/WO2005072066A1/ja
Application granted granted Critical
Publication of DK1719774T3 publication Critical patent/DK1719774T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/106—Primate
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
DK05704239.2T 2004-01-30 2005-01-28 Terapeutisk middel mod diabetisk makulaødem DK1719774T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004022547 2004-01-30
PCT/JP2005/001187 WO2005072066A1 (ja) 2004-01-30 2005-01-28 糖尿病黄斑症の予防又は治療剤

Publications (1)

Publication Number Publication Date
DK1719774T3 true DK1719774T3 (da) 2012-07-16

Family

ID=34823835

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05704239.2T DK1719774T3 (da) 2004-01-30 2005-01-28 Terapeutisk middel mod diabetisk makulaødem

Country Status (11)

Country Link
US (2) US7910615B2 (da)
EP (1) EP1719774B1 (da)
JP (2) JP4014053B2 (da)
KR (1) KR101111411B1 (da)
CN (1) CN100537574C (da)
AT (1) ATE555117T1 (da)
AU (1) AU2005207906B2 (da)
CA (1) CA2554679C (da)
DK (1) DK1719774T3 (da)
ES (1) ES2386094T3 (da)
PL (1) PL1719774T3 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2393271T3 (es) * 2005-12-16 2012-12-19 Sanwa Kagaku Kenkyusho Co., Ltd Agente para la prevención y tratamiento de la insuficiencia renal aguda
CA2642933A1 (en) * 2006-02-20 2007-08-30 Sanwa Kagaku Kenkyusho Co., Ltd. Prophylactic or therapeutic agent for cerebral ischemia or cerebral ischemic reperfusion injury in stroke
JP5363123B2 (ja) * 2007-01-31 2013-12-11 株式会社三和化学研究所 網膜神経又は視神経の保護剤
BR112012017071A2 (pt) * 2010-01-14 2016-04-12 Univ Nagoya City produto farmacêutico para prevenir ou tratar distúrbios acompanhados da agiogênese ocular e/ou do aumento da permeabilidade vascular ocular
JP6187985B2 (ja) * 2015-07-14 2017-08-30 国立大学法人佐賀大学 ノックアウト非ヒト動物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61200991A (ja) 1985-03-04 1986-09-05 Sanwa Kagaku Kenkyusho:Kk スピロ―３―ヘテロアゾリジン化合物、その製法及びそれを有効成分とする糖尿病合併症の予防及び治療剤
JP2672949B2 (ja) 1987-10-20 1997-11-05 株式会社芝浦製作所 エミッションコントロール装置
JP2976230B2 (ja) * 1989-12-20 1999-11-10 大塚製薬株式会社 糖尿病ラット
JP3025917B2 (ja) * 1990-12-19 2000-03-27 大塚製薬株式会社 インシュリン非依存性糖尿病ラット
US5639482A (en) * 1993-11-10 1997-06-17 Crary; Ely J. Composition for control and prevention of diabetic retinopathy
JPH07242547A (ja) 1994-03-02 1995-09-19 Sanwa Kagaku Kenkyusho Co Ltd 糖尿病性単純網膜症の進行阻止剤乃至治療剤
DE69519219T2 (de) 1994-12-28 2001-02-22 Sanwa Kagaku Kenkyusho, Co. Verwendung von (2S,4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazoline]-2-carboxamid zur Behandlung von Keratopathie
JP3603129B2 (ja) 1994-12-28 2004-12-22 株式会社三和化学研究所 糖尿病性角膜症の治療剤
JPH09301861A (ja) * 1996-05-13 1997-11-25 Showa Denko Kk ラジカル疾患用注射・点滴薬剤
AU4725697A (en) * 1996-11-01 1998-05-29 Shionogi & Co., Ltd. Model mouse for human diseases
US6479729B1 (en) * 1998-02-06 2002-11-12 The Johns Hopkins University Mouse model for ocular neovascularization
EP1066832B1 (en) * 1998-02-06 2005-11-16 Cci Corporation Preventives and remedies for ischemic reflow disorder
JP2000270713A (ja) * 1999-03-23 2000-10-03 Kennetto:Kk 糖尿病態モデル動物及びその製造方法並びに糖尿病態モデル動物の選定方法
US6426341B1 (en) * 1999-06-30 2002-07-30 Pfizer Inc. Treatment for diabetic complications
US20020068740A1 (en) * 1999-12-07 2002-06-06 Mylari Banavara L. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications

Also Published As

Publication number Publication date
KR20060126547A (ko) 2006-12-07
CA2554679C (en) 2012-09-25
EP1719774A2 (en) 2006-11-08
WO2005072066A3 (ja) 2005-10-06
ES2386094T3 (es) 2012-08-08
CN1914211A (zh) 2007-02-14
JP2008029346A (ja) 2008-02-14
US8097640B2 (en) 2012-01-17
JPWO2005072066A1 (ja) 2007-09-06
ATE555117T1 (de) 2012-05-15
CN100537574C (zh) 2009-09-09
AU2005207906A1 (en) 2005-08-11
US20070293556A1 (en) 2007-12-20
WO2005072066A2 (ja) 2005-08-11
AU2005207906B2 (en) 2009-10-22
US7910615B2 (en) 2011-03-22
EP1719774A4 (en) 2009-05-06
JP4014053B2 (ja) 2007-11-28
EP1719774B1 (en) 2012-04-25
PL1719774T3 (pl) 2012-09-28
CA2554679A1 (en) 2005-08-11
KR101111411B1 (ko) 2012-03-13
US20100305177A1 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
EP1614676A4 (en) PHOSPHORUS TRANSPORT IN VIVO INHIBITOR COMPOUND AND MEDICAMENT CONTAINING THE SAME
BR0314761A (pt) Composto de adenina e seu uso
BRPI0515488A (pt) derivados de heterocìclicos e seu uso como agentes terapêuticos
WO2007046867A3 (en) Piperidine derivatives and their uses as therapeutic agents
WO2007044085A3 (en) Heteroaryl compounds and their uses as therapeutic agents
BRPI0515482A (pt) derivados heterocìclicos e seus usos como agentes terapêuticos
AR044543A1 (es) Derivados de pirazolo-quinazolina, un procedimiento para su preparacion y su uso como inhibidor de quinasa
NZ530782A (en) Aminoisoxazole derivatives active as kinase inhibitors
EP1792927A4 (en) NEW BLOCK COPOLYMER, MICELLA PREPARATION AND ANTICROPHIDE CONTAINING THIS AS ACTIVE INGREDIENTS
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
BRPI0412343A (pt) derivados de piridazina e seu uso como agentes terapêuticos
NO20070576L (no) Nye hydantionderivater for behandling av obstruktive luftveissykdommer.
DK1719774T3 (da) Terapeutisk middel mod diabetisk makulaødem
AU2003257588A1 (en) REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS
AR054790A1 (es) Metodos para el tratamiento de disfuncion sexual
TW200745136A (en) 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid derivatives
DK1778680T3 (da) Spirocykliske cyclohexaderivater
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
RU2008114048A (ru) Комбинации, включающие ингибитор рецептора сэфр (сосудистого эндотелиального фактора роста) и агент, увеличивающий проницаемость
AR054272A1 (es) Derivados de 3- aminopirrilidinas tri, tetra - sustituidos
RU2012134639A (ru) Фармацевтический препарат для предупреждения и лечения нарушений, сопровождающихся глазным ангиогенезом и/или повышенной проницаемостью сосудов глаза
WO2008008701A3 (en) Substituted cyclopentane derivatives as therapeutic agents
US6436944B1 (en) Combination effective for the treatment of impotence
BR112019000290B1 (pt) Prófármacos de fósforo dos estimuladores da sgc
NO20072089L (no) Benzimidazolderivater, sammensetninger som inneholder dem, fremstilling derav og anvendelse derav